Table 2 HPLC-UV analysis condition
| Anticancer drug | Column Temperature (°C) |
Mobile phase (Volume%) |
Flow rate (mL/min) |
Detection Wavelength (nm) |
Determination limit (μg/mL) |
|---|---|---|---|---|---|
| CPA | 40 | H2O : CH3CN = 75 : 25 | l.0 | 195 | 5 |
| IFM | 40 | H2O : CH3CN = 54 : 46 | 1.0 | 198 | 1.0 |
| MTX | 40 | 0.1%CH3COOH:CH3OH = 80:20 | l.0 | 307 | 0.1 |
| 5-FU | 25 | 10mM KH2PO4 :CH3OH = 90 : 10 | l.0 | 285 | 0.75 |
| Ara-C | 40 | 50mMPBS(pH6.8):CH3OH = 99.5:0.5 | 1.0 | 275 | 0.1 |
| GEM | 40 | 10mMPBS(pH7.5):CH3OH = 98:2 | 1.0 | 275 | 0.1 |
| ADR | 40 | 90% CH3CN:50mM PBS (pH3.2) = 68 : 32 | 1.0 | 230 | 1.0 |
| Epi-ADR | 40 | 20mM PBS (pH2.0) : CH3CN = 69 : 31 | l.0 | 254 | 0.2 |
| PTX | 40 | CH3CN : H2O : CH3OH = 50 : 30 : 20 | l.0 | 236 | 0.5 |
| DTX | 40 | 10mMPBS(pH3.0):CH3CN = 50:50 | 1.0 | 230 | 0.1 |
| VP-16 | 40 | 0.007%TEA, 20mMPBS (pH5.2):CH3CN:CH3OH = 63:19:18 | 1.0 | 285 | 0.1 |
| CPT-11 | 40 | 50mM KH2PO4, 7.5mM Bu4NBr : CH3CN = 83 : 17 | l.0 | 254 | 0.5 |